The news correspondents obtained a quote from the research from the Technion-Israel Institute of Technology, "Apolipoprotein E knockout mice aged 16 or 32 weeks were randomly divided into eplerenone (100 mg.kg(-1).d(-1)) or vehicle treatment for 14 weeks. Eplerenone reduced atherosclerotic lesion size by 51% only in early ATS. In peritoneal macrophages obtained from these mice, eplerenone reduced messenger RNA expression of pro-inflammatory markers, interleukin 6, tumor necrosis factor a, monocyte chemotactic protein 1, and increased anti-inflammatory marker arginase 1 to a greater extent in early compared with advanced ATS. These changes correspond to macrophage polarization toward alternative inflammatory phenotype. Messenger RNA expression of the mineralocorticoid receptor and aldosterone synthase were also reduced by eplerenone to a greater extent in early ATS, and these might increase the sensitivity of macrophages to mineralocorticoid blockade in early ATS."
According to the news reporters, the research concluded: "The results of the present study point to the benefits of early initiation of treatment with eplerenone in reducing experimental ATS."
For more information on this research see: Eplerenone Reduced Lesion Size in Early but Not Advanced Atherosclerosis in Apolipoprotein E-Deficient Mice. Journal of Cardiovascular Pharmacology, 2012;60(6):508-512. Journal of Cardiovascular Pharmacology can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Lippincott Williams and Wilkins - www.lww.com; Journal of Cardiovascular Pharmacology - journals.lww.com/cardiovascularpharm/pages/default.aspx)
Our news journalists report that additional information may be obtained by contacting A. Raz-Pasteur, Technion Israel Inst Technol, Rappaport Fac Med, Rappaport Family Inst Res Med Sci, Dept. of Anat, Haifa, Israel.
Keywords for this news article include: Asia, Haifa, Israel, Hormones, Apoproteins, Apolipoproteins, Atherosclerosis, Arteriosclerosis, Mineralocorticoids, Cardiovascular Diseases, Arterial Occlusive Diseases, Cardiovascular Drugs and Therapies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.